Market size, company revenue, drug approvals, clinical trials, regulation, hospitals, doctors, drug spending, labs and devices
DataPorium delivers healthcare sector analytics across pharmaceuticals, biotech, and medical devices. Track company performance, compare players within a sub-sector, and study market-share dynamics to see who is gaining ground — turning raw industry data into clear competitive intelligence for investors and analysts.
Healthcare is a vast, fast-moving sector spanning drug makers, biotech innovators, medical-device manufacturers, insurers, and care providers. What sets it apart is how much value hinges on competitive position: a single approval, patent, or shift in market share can reshape an entire category. That is why healthcare analytics works best when it goes beyond price to capture who is winning and why. The same data is also available through the DataPorium financial data API.
Effective sector analysis starts by grouping companies into comparable segments — large-cap pharma, emerging biotech, devices, services — then comparing growth, profitability, and market share within each. Rising share often signals a stronger product pipeline or pricing power, while eroding share can foreshadow trouble. Because healthcare is defensive and demographic-driven, pairing competitive intelligence with economic indicators helps you separate durable leaders from short-term movers.
The Drug Approvals section lists every US approval of a new drug, a biologic (including vaccines, blood products and cell and gene therapies), a generic drug and a new use, with novel drugs marked, and the approvals of 13 other countries. You can filter by country, generic name, company, stock symbol, year, type, review, kind and form, sort every column, and open a detail card for each approval. The Clinical Trials section covers every registered clinical study with its phase, status, conditions, drugs, sponsor, dates and enrollment, and both are updated daily.
It covers pharmaceutical, biotech, and medical-device companies, along with sector trends and competitive intelligence such as market share and product positioning.
Track company performance, compare players within a sub-sector, and study market-share dynamics to understand who is gaining or losing ground across drugs, devices, and services.
Healthcare is a large, defensive sector driven by innovation, regulation, and demographics, which makes competitive intelligence especially valuable for spotting winners early.
The Drug Approvals section lists every US approval of a new drug, a biologic, a generic and a new use, and the Clinical Trials section covers every registered clinical study with its phase, status, conditions and sponsor. On the stock page, the Drug Pipeline tab shows the approvals and trials of one company.
52 novel drugs were approved in the United States in 2026 as of October 14, 2026, after 54 in 2025. A novel drug is the first approval of a new active ingredient.
AstraZeneca PLC (AZN) is the lead sponsor of 560 active clinical trials, 195 of them in phase 3. Drugs in its active phase 3 trials include ALXN2220, FLOT Chemotherapy, Durvalumab, Torvutatug samrotecan.
Novartis AG (NVS) is the lead sponsor of 366 active clinical trials, 90 of them in phase 3. Drugs in its active phase 3 trials include Abelacimab, zigakibart, atrasentan, Remibrutinib.
Pfizer Inc. (PFE) is the lead sponsor of 254 active clinical trials, 87 of them in phase 3. Drugs in its active phase 3 trials include Abrocitinib, Berobenatide, PF-08634404, Pembrolizumab.
Roche Holding AG (ROG.SW) is the lead sponsor of 246 active clinical trials, 88 of them in phase 3. Drugs in its active phase 3 trials include NXT007, Trontinemab, Afimkibart, Giredestrant.
Johnson & Johnson (JNJ) is the lead sponsor of 240 active clinical trials, 74 of them in phase 3. Drugs in its active phase 3 trials include Ramantamig, Daratumumab, Lenalidomide, Bortezomib.
AbbVie Inc. (ABBV) is the lead sponsor of 236 active clinical trials, 60 of them in phase 3. Drugs in its active phase 3 trials include Telisotuzumab Adizutecan, Docetaxel, Ramucirumab, Etentamig.
Bristol-Myers Squibb Company (BMY) is the lead sponsor of 236 active clinical trials, 66 of them in phase 3. Drugs in its active phase 3 trials include BMS-986353, Fludarabine, Cyclophosphamide, Tocilizumab.
Merck & Co., Inc. (MRK) is the lead sponsor of 233 active clinical trials, 99 of them in phase 3. Drugs in its active phase 3 trials include Sotatercept, Ensifentrine, Sac-TMT, Pembrolizumab and Berahyaluronidase alfa.
Eliquis cost Medicare Part D $20.77 billion in 2024, the most of any drug, ahead of Ozempic ($12.97 billion) and Jardiance ($11.43 billion).
Eli Lilly's Q2 2026 revenue rose 48% to $23.0 billion on Mounjaro and Zepbound, while Novo Nordisk's sales grew 3%. Novo shares fell 21% in Q3.
A health savings account used as a retirement account is deductible going in, untaxed while growing and tax free for medical costs: $8,750 a year for 25 years at 7% builds about $553,000.